Mono Pharmacare share price
NSE: MONOPHARMAPharmaceuticals & Biotechnology
Last close ₹8.50down ₹0.40 (4.49%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹8.90.
52-week range of traded prices to 23 Oct 2026
₹7.50Low, 10 Aug 2026₹22.05High, 28 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹15 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 16 Jul 2026
- 42.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 16 Jul 2026
- 0.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 16 Jul 2026
- 1.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 16 Jul 2026
- 1.79
- Volume, NSEVolume. Shares traded on the last trading day.
- 2,000
Results
Consolidated; ₹ crore, the charts by years to March, the table by half year.Half-yearly results
Half year to Mar 2026, against the half year beforeFiled 16 Jul
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹99 Crup 49.95%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹0.33 Crup 1,417.35%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 0.3%
Revenue by year
Peak revenue ₹168 Cr, year to Mar 2025
Net profit by year, a loss in red
| ₹ crore | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025Filed 31 May | Sep 2025Filed 2 Dec | Mar 2026Filed 16 Jul |
|---|---|---|---|---|---|---|
| Revenue | 66.5 | 55.8 | 87.2 | 81.2 | 66.3 | 99.4 |
| Net profit | 1.9 | 0.6 | 2.3 | 0.7 | 0.0 | 0.3 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 2.8% | 1.0% | 2.6% | 0.9% | 0.0% | 0.3% |
Consolidated. The 6 half years from Sep 2023, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Single segment, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −51.7% | −88.6% | +322.3% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Mono Pharmacare in market cap. 1 company in the table last traded before then: its row is priced on its last trade.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Span DivergentSDL | 17 | – | 1.1 | – | +171.7% | – | – | −24.0% | 0.00% |
 Venmax Drugs and PharmaceuticalsVENMAX | 17 | – | – | – | +385.7% | – | – | – | 0.00% |
 Star Source Multi TradeSTARSOURCE | 16 | – | 12.3 | – | – | – | −0.5% | −3.1% | 0.00% |
| Desh Rakshak AushdhalayaDESHRAK | 15 | 27.8 | 1.2 | 13.0 | −24.3% | – | 4.7% | 5.8% | 0.00% |
 Beryl DrugsBERLDRG | 13 | 20.1 | 1.3 | 8.1 | +8.3% | +169.1% | 6.4% | 3.1% | 0.00% |
 Unjha FormulationsUNJHAFOR | 12 | 26.2 | 3.2 | 14.6 | +13.0% | +386.7% | 13.5% | 15.2% | 0.00% |
 Ortin GlobalORTINGLOBE | 10 | – | 8.4 | – | −58.3% | – | −56.2% | −52.2% | 0.00% |
 Dipna PharmachemDPL | 10 | – | – | – | – | – | – | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
17 Sep · Corporate action
9 Sep · Updates
Mono Pharmacare share price by year
Each calendar year to 2025.Mono Pharmacare share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 15.20 | −56.1% | 34.65 | 14.95 |
| 2024 | 34.65 | −29.3% | 72.15 | 32.10 |
| 2023 | 49.00 | – | 53.85 | 29.30 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2023 is from its first session, 7 Sep 2023.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 8.50 | 8.50 | 8.50 | 8.50 | 8.50 | 2,000 | – |
| 9 Oct 2026 | 8.45 | 8.90 | 8.45 | 8.90 | 8.74 | 14,000 | 100.0% |
| 8 Oct 2026 | 8.00 | 8.75 | 8.00 | 8.50 | 8.29 | 12,000 | – |
| 7 Oct 2026 | 8.05 | 8.40 | 8.05 | 8.40 | 8.18 | 6,000 | 66.7% |
| 6 Oct 2026 | 8.30 | 8.30 | 8.30 | 8.30 | 8.30 | 2,000 | 100.0% |
| 30 Sep 2026 | 8.55 | 8.55 | 8.55 | 8.55 | 8.55 | 2,000 | 100.0% |
| 29 Sep 2026 | 8.55 | 8.55 | 8.55 | 8.55 | 8.55 | 4,000 | 100.0% |
| 28 Sep 2026 | 8.20 | 9.00 | 8.20 | 9.00 | 8.68 | 46,000 | 60.9% |
| 25 Sep 2026 | 8.60 | 8.60 | 8.60 | 8.60 | 8.60 | 10,000 | 100.0% |
| 23 Sep 2026 | 8.20 | 8.20 | 8.20 | 8.20 | 8.20 | 4,000 | 100.0% |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Mono Pharmacare Limited
- NSE symbol
- MONOPHARMA
- ISIN
- INE0OIP01012
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Sep 2023
- Face value
- ₹10